Rainbow Coral and its joint venture partner, Therakine, have reached a major new milestone in the development of a revolutionary new drug delivery technology. The companies reached terms to initiate Phase II of research and analysis on a ...
Tags: RBCC, Drug Delivery Development
Baxter International has submitted a biologics license application (BLA) to the US Food and Drug Administration (FDA) for the approval of a recombinant antihemophilic porcine sequence factor VIII called 'OBI-1' for the treatment of patients ...
Baxter International has filed an application to the US Food and Drug Administration (FDA) for a pediatric indication for Rixubis [Coagulation Factor IX (Recombinant)] to treat hemophilia B. The submission was based on a Phase II/III ...
OncoMed Pharmaceuticals and Celgene have entered into an agreement to jointly develop and commercialize about six anti-cancer stem cell (CSC) product candidates from OncoMed's biologics pipeline, including demcizumab (OMP-21M18, Anti-DLL4). ...
Tags: clinical studies, Medicine, OncoMed
Bolton Medical, a medical device manufacturer, has initiated its Phase II US clinical trial to study the safety and effectiveness of the Treovance abdominal stent-graft with Navitel delivery system. The first two cases were performed on ...
InnaVirVax, a biopharmaceutical company, has commenced a Phase II clinical trial evaluating the therapeutic properties of the VAC-3S vaccine when combined with standard antiretroviral therapy (ART) in the course of HIV-1 infection. The ...
The just-concluded 18th Congress of Chinese Communist Party explicitly called for implementation of "Biological Civilization" strategy. The move restored confidence into offshore wind power and green energy industry which are still in ...
The US Food and Drug Administration (FDA) has granted orphan drug designation to Conatus Pharmaceuticals' drug candidate emricasan for the treatment of liver transplant patients with reestablished fibrosis to delay the progression to ...
Eisai has filed an application for the proton pump inhibitor Pariet in Japan looking for a further indication expansion for use in the prevention of recurrent gastric or duodenal ulcer caused by low-dose aspirin therapy as well as the ...
Navidea Biopharmaceuticals will collaborate with the University of Alabama at Birmingham (UAB) on a clinical study that will assess the safety and activity of a radiolabeled, humanized monoclonal antibody from its RIGS (radio-immuno-guided ...
VBL Therapeutics has secured fast track status from the US Food and Drug Administration (FDA) for its lead oncology drug VB-111, for prolongation of survival in patients with Recurrent Glioblastoma Multiforme (rGBM). VB-111 was already ...
Theraclone Sciences has received notification from the Biomedical Advanced Research and Development Authority (BARDA) informing the company that their proposal, 'Broad-spectrum anti-influenza A M2e fully human monoclonal antibody TCN-032: ...
Signum Dermalogix, a biopharmaceutical company, has announced that the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded the company a Small Business Innovation Research (SBIR) Phase II grant totaling ...
Johnson & Johnson (JNJ) subsidiary Janssen Biotech and Pharmacyclics (PCYC) have won approval from the US Food and Drug Administration (FDA) for their breakthrough therapy Imbruvica (ibrutinib) to treat patients with mantle cell lymphoma ...
Tags: Johnson&Johnson, MCL Patients
Alnylam Pharmaceuticals, a RNAi therapeutics company, announced that the US Food and Drug Administration (FDA) has granted fast track designation to patisiran (ALN-TTR02) for the treatment of transthyretin (TTR)-familial amyloid ...
Tags: Alnylam, Fast Track Designation